IN2012DN06432A - - Google Patents

Info

Publication number
IN2012DN06432A
IN2012DN06432A IN6432DEN2012A IN2012DN06432A IN 2012DN06432 A IN2012DN06432 A IN 2012DN06432A IN 6432DEN2012 A IN6432DEN2012 A IN 6432DEN2012A IN 2012DN06432 A IN2012DN06432 A IN 2012DN06432A
Authority
IN
India
Prior art keywords
cells
formula
mammalian cells
cardiomyocyte
radicals
Prior art date
Application number
Other languages
English (en)
Inventor
Marko Mihovilovic
Michael Schnuerch
Moumita Koley
Karlheinz Hilber
Xaver Koenig
Original Assignee
Univ Wien Tech
Univ Wien Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Tech, Univ Wien Med filed Critical Univ Wien Tech
Publication of IN2012DN06432A publication Critical patent/IN2012DN06432A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657Cardiomyocytes; Heart cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/40Nucleotides, nucleosides or bases

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN6432DEN2012 2009-12-28 2010-12-28 IN2012DN06432A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA2044/2009A AT509266B1 (de) 2009-12-28 2009-12-28 Substituierte pyridine und pyrimidine
PCT/AT2010/000495 WO2011079343A2 (en) 2009-12-28 2010-12-28 Substituted pyridines and pyrimidines

Publications (1)

Publication Number Publication Date
IN2012DN06432A true IN2012DN06432A (cs) 2015-10-09

Family

ID=43825275

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6432DEN2012 IN2012DN06432A (cs) 2009-12-28 2010-12-28

Country Status (5)

Country Link
US (1) US8986994B2 (cs)
EP (1) EP2519501B1 (cs)
AT (1) AT509266B1 (cs)
IN (1) IN2012DN06432A (cs)
WO (1) WO2011079343A2 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT511441B1 (de) 2011-09-21 2012-12-15 Univ Wien Tech Triazin-derivate als differenzierungsbeschleuniger
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
JP2022508945A (ja) 2018-10-22 2022-01-19 カデント セラピューティクス,インコーポレーテッド カリウムチャネルモジュレーターの結晶形態
KR20250152723A (ko) * 2024-04-16 2025-10-24 경북대학교 산학협력단 신규한 피리미딘 유도체 화합물 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063173A1 (de) * 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
HUP0401711A3 (en) * 2001-06-26 2009-07-28 Bristol Myers Squibb Co N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2005068437A1 (en) * 2004-01-16 2005-07-28 Novartis Ag 2, 4 - diaminopyrimidines and their use for inducing cardiomyogenesis
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006037117A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
WO2011079343A2 (en) 2011-07-07
WO2011079343A3 (en) 2011-10-13
AT509266B1 (de) 2014-07-15
US20120294835A1 (en) 2012-11-22
AT509266A1 (de) 2011-07-15
US8986994B2 (en) 2015-03-24
EP2519501B1 (en) 2015-04-22
EP2519501A2 (en) 2012-11-07

Similar Documents

Publication Publication Date Title
MY161199A (en) Fused tricyclic dual inhibitors of cdk 4/6 and flt3
IN2012DN06432A (cs)
NZ741985A (en) Prodrugs of fumarates and their use in treating various diseases
IN2014CN04037A (cs)
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
PL2231568T3 (pl) Sposób wytwarzania etanolu z kwasu etanowego i wodoru
MX2014005285A (es) Compuestos biciclicos de piperazina.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
IN2014CN03265A (cs)
PH12012502128B1 (en) Chemical compounds
MX2009012623A (es) Moduladores de cinasa heterociclicos.
UA91895C2 (en) Thiazole compounds and methods of use
GB0920703D0 (en) Compositions containing satiogens and methods of use
CY1107014T1 (el) Χρηση θρεπτικου μεσου κυτταροκαλλιεργειας ελευθερου ορου για την παραγωγη il-18bp σε κυτταρα θηλαστικων
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MY171831A (en) Novel fused pyrimidine compound or salt thereof
DK1999160T3 (da) Acryleret hyaluronsyre
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
PH12013501089A1 (en) Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
MX2009011255A (es) Proceso para preparar capecitabina.
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
IN2015DN03751A (cs)